[HTML][HTML] Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy
Background Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
HM Maeng, BN Moore, M Terabe, LC England… - Frontiers in …, 2021 - elibrary.ru
The study was approved by the Institutional Review Board of the National Cancer Institute
(NCI), National Institutes of Health (NIH) and conducted in accordance with institutional and …
(NCI), National Institutes of Health (NIH) and conducted in accordance with institutional and …
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
HM Maeng, BN Moore, H Bagheri… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy.
HM Maeng, BN Moore, H Bagheri… - Frontiers in …, 2021 - europepmc.org
Background Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
[PDF][PDF] Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. Front
HM Maeng, BN Moore, H Bagheri, SM Steinberg… - Oncol, 2021 - academia.edu
Background: Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
[HTML][HTML] Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
HM Maeng, BN Moore, H Bagheri… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and
Preliminary Clinical Efficacy - PMC Back to Top Skip to main content NIH NLM Logo Access …
Preliminary Clinical Efficacy - PMC Back to Top Skip to main content NIH NLM Logo Access …
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
HM Maeng, BN Moore, H Bagheri… - FRONTIERS IN …, 2022 - books.google.com
Background: Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
[PDF][PDF] Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. Front
HM Maeng, BN Moore, H Bagheri, SM Steinberg… - Oncol, 2021 - academia.edu
Background: Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …